IBRX Q1 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11,000+83.3% YoY

Gross Profit

$11,000100.0% margin

Operating Income

-$25M-223418.2% margin

Net Income

-$25M-222863.6% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-21.4%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$15M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$304M

Total Liabilities

$25M

Stockholders' Equity

$278M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11,000	$6,000	+83.3%
Gross Profit	$11,000	$6,000	+83.3%
Operating Income	-$25M	-$31M	+20.2%
Net Income	-$25M	-$31M	+20.0%